HealthRX vs Trimi Health
The recorded semaglutide annual-plan totals match at $1,188. HealthRX also lists shorter plans; choosing between them requires comparing the upfront commitment and cancellation terms.
Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
HealthRX
Partner
$165/mo
Four plan lengths are priced in one table, each with its total, its per-month rate and its renewal rate. The advertised floor needs a full year paid up front; buying month to month is $165 for semaglutide and $214 for tirzepatide, held flat at every dose with nothing charged outside it.
- Four plan lengths priced, each with its total and its per-month rate
- One price at every dose, so titration carries no increase
- Consultation, prescription, medication and overnight shipping in the figure
- Full refund stated where a provider does not approve
- The annual table's $99 monthly equivalent requires $1,188 up front
- Month-to-month costs $165, two thirds more than the headline
- The compounding pharmacy is described but not named
- Injection only — no oral product on either molecule
Pick it for: Comparing shorter plans with the annual commitment before paying
Not for: Anyone who wants to stop after a month or two and needs the headline rate to hold.
Trimi Health
Editorial
$99/mo
$99 semaglutide against $125 tirzepatide. The $26 step between molecules is under half the typical distance in this market, which matters if you expect to escalate onto tirzepatide later. Flat across doses, fifty states.
- $26 between molecules is unusually narrow for this market
- Flat across the dose ladder on both
- $99 semaglutide is below the middle of the field
- Financing offered on the annual charge
- Annual plan billed upfront, not a rolling month
- No month-to-month figure published for comparison
- Injection only
- Compounding pharmacy is not named
Pick it for: Considering annual financing after checking refund and repayment terms
Not for: Anyone who wants to stop after a month or two.
Our verdict
The recorded annual semaglutide plans both total $1,188 upfront, expressed as $99 a month. HealthRX also lists shorter plans and a rolling subscription; Trimi's recorded offer is an annual commitment with financing. That financing spreads payments, not the treatment term. HealthRX's refund policy separates canceling future renewals from returning dispensed medication, so cancellation does not establish a full refund for an unfinished year. Before prepaying either seller, request the unused-supply refund rule, renewal deadline and any remaining financing obligation. The monthly equivalent alone cannot tell you what stopping early will cost.
What actually separates them
HealthRX and Trimi Health differ on published price, states a milligram dose, names its pharmacy and where you can use it. The table summarizes those terms; confirm any details it does not cover with the provider.
HealthRX’s comparison figure is $66 higher than Trimi Health’s — a 67% difference between the listed rates. These figures do not establish equivalent prescribed doses, supply or care. Confirm the selected product, full payment obligation and next charge.
At unchanged rates, a twelve-month illustration is about $1,188 at Trimi Health against $1,980 at HealthRX — a difference of $792. This is not a quote for a year of care: actual charges depend on prescribed supply, purchase terms and renewals.
| HealthRX | Trimi Health | |
|---|---|---|
| Published price | $165/mo | $99/mo |
| States a milligram dose | Yes | No |
| Names its pharmacy | No | Yes |
| Where you can use it | All 50 states | 50 states |
Before you choose either
Only one of these two publishes a milligram dose, which makes a straight price comparison impossible: you can tell what each costs, but only one tells you what you get. Ask the other what dose its price buys before you commit, then set both numbers against every published price we hold. A seller that will not answer that question has told you something.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.